Core Viewpoint - The announcement highlights the completion of patient enrollment for a real-world study of OT-703 (ILUVIEN), a non-biodegradable fluocinolone acetonide intravitreal implant for treating diabetic macular edema (DME) in Hainan, China [1] Group 1: Product Overview - OT-703 is an injectable, non-biodegradable fluocinolone acetonide implant that provides continuous release of the drug for up to 36 months [1] - It is the only FDA-approved intravitreal implant for DME that offers a sustained release for three years [1] Group 2: Regulatory Approvals - OT-703 has received regulatory approval from the U.S. Food and Drug Administration (FDA) and is marketed under the brand name "ILUVIEN" [1] - In December 2023, OT-703 was approved by the Hong Kong Pharmacy and Poisons Board for registration as a pharmaceutical product under the Pharmacy and Poisons Ordinance [1] Group 3: Licensing Agreement - In April 2021, the company entered into an exclusive licensing agreement with Alimera Sciences, Inc., granting the company exclusive rights to develop and commercialize ILUVIEN in Greater China, South Korea, and 11 Southeast Asian countries [1] Group 4: Study Details - The real-world study involved a total of 195 patients enrolled in Hainan, China [1]

Core Insights - Hainan Boao Lecheng International Medical Tourism Pilot Zone is becoming a crucial link between rare disease drug companies and patients through policy iterations, insurance collaboration, and multi-dimensional empowerment [1] Policy Iteration - The policy framework for rare disease drug assurance in Lecheng has evolved through three versions: - Version 1.0 focuses on introducing licensed drugs and devices to allow some patients to access urgently needed medications [2] - Version 2.0 allows the use of real-world data from rare disease drugs for expedited domestic approval [2] - Version 3.0 expands the coverage to include special medical foods, health products, and new biomedical technologies [2] Special Drug Insurance - Lecheng has launched a special drug insurance plan to significantly reduce the financial burden on patients, with premiums starting at 49 yuan and coverage up to 2 million yuan for 120 types of global special drugs and 10 types of imported devices [3] Future Initiatives - Lecheng aims to strengthen the connection between rare disease drug companies and patients by leveraging special drug policies and introducing more special medical foods [4] - The zone has received approval for biomedical new technology policies, allowing clinical research and application transformation for technologies that have completed Phase II trials [4] - The initiative includes collaboration with the National Medical Products Administration and the National Healthcare Security Administration to expedite drug registration and insurance access [4]